PKI-402
Based on 11 publication(s) in Google Scholar
PKI-402 is a selective, reversible, ATP-competitive inhibitor of PI3K, including PI3K-α mutants, and mTOR (IC50=2, 3, 7,14 and 16 nM for PI3Kα, mTOR, PI3Kβ, PI3Kδ and PI3Kγ).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.17%
- CAS No.: 1173204-81-3
- Formule: C29H34N10O3
- Masse moléculaire:570.65
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) PKI-402
More- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. [Abstract]
- J Exp Clin Cancer Res. 2024 Oct 10;43(1):284. [Abstract]
- Cell Prolif. 2019 May;52(3):e12609. [Abstract]
- Int Immunopharmacol. 2025 Dec 24:170:116055. [Abstract]
- Int Immunopharmacol. 2023 Oct:123:110793. [Abstract]
- Molecules. 2020 Apr 23;25(8):1980. [Abstract]
- Sci Rep. 2022 Apr 12;12(1):6090. [Abstract]
- Lung. 2025 Jun 16;203(1):69. [Abstract]
- J Biochem Mol Toxicol. 2025 Jun;39(6):e70356. [Abstract]
- Chem Biodivers. 2025 Jun;22(6):e202402598. [Abstract]
- Heliyon. 2024 May 10;10(10):e31112. [Abstract]
-
Flow Cytometry
Activité biologique
|
PI3Kα 2 nM (IC50) |
PI3Kα-H1047R 3 nM (IC50) |
PI3Kα-E545K 3 nM (IC50) |
PI3Kβ 7 nM (IC50) |
PI3Kδ 14 nM (IC50) |
PI3Kγ 16 nM (IC50) |
mTOR 3 nM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MDA-MB-361 | IC50 |
10 nM
Compound: 77
|
Cytotoxicity against human MDA-MB-361 cells
Cytotoxicity against human MDA-MB-361 cells
|
[PMID: 25387153] |
| MDA-MB-361 | IC50 |
5 nM
Compound: 3, PKI-402
|
Inhibition of Akt T308 phosphorylation in human MDA-MB-361 cells after 4 hrs by Western blotting
Inhibition of Akt T308 phosphorylation in human MDA-MB-361 cells after 4 hrs by Western blotting
|
[PMID: 19968288] |
| MDA-MB-361 | IC50 |
8 nM
Compound: 2, PKI-402
|
Growth inhibition of human MDA-MB-361 cells after 72 hrs
Growth inhibition of human MDA-MB-361 cells after 72 hrs
|
[PMID: 21763134] |
| MDA-MB-361 | IC50 |
8 nM
Compound: 3, PKI-402
|
Cytotoxicity against human MDA-MB-361 cells with Her2+/PI3KCA mutant after 72 hrs
Cytotoxicity against human MDA-MB-361 cells with Her2+/PI3KCA mutant after 72 hrs
|
[PMID: 19968288] |
| PC-3 | IC50 |
21 nM
Compound: 2, PKI-402
|
Growth inhibition of human PC3 cells after 72 hrs
Growth inhibition of human PC3 cells after 72 hrs
|
[PMID: 21763134] |
| PC-3 | IC50 |
21 nM
Compound: 3, PKI-402
|
Cytotoxicity against human PC3 cells with PTEN mutant after 72 hrs
Cytotoxicity against human PC3 cells with PTEN mutant after 72 hrs
|
[PMID: 19968288] |
| Sf9 | IC50 |
1 nM
Compound: 2, PKI-402
|
Inhibition of human PI3Kalpha expressed in SF9 insect cells after 2 hrs by fluorescence polarization assay
Inhibition of human PI3Kalpha expressed in SF9 insect cells after 2 hrs by fluorescence polarization assay
|
[PMID: 21763134] |
| Sf9 | IC50 |
9 nM
Compound: 2, PKI-402
|
Inhibition of human PI3Kgamma expressed in SF9 insect cells after 2 hrs by fluorescence polarization assay
Inhibition of human PI3Kgamma expressed in SF9 insect cells after 2 hrs by fluorescence polarization assay
|
[PMID: 21763134] |
PKI-402 is an equipotent inhibitor of class I PI3K, including the E545K and H1047R PI3K-α mutants (IC50=2, 3 and 3 nM for PI3Kα, PI3Kα-H1047R and PI3Kα-E545K, respectively). PKI-402 causes in vitro growth inhibition of human tumor cell lines derived from a diverse set of human tumor tissues, including breast, brain (glioma), pancreas, and non-small cell lung cancer (NSCLC) tissues. PKI-402 inhibits MDA-MB-361 [breast: Her2+ and PIK3CA mutant (E545K)], with an IC50 of 6 nM. PKI-402 inhibits HCT116 (K-Ras and PIK3CA mutant) with an IC50 of 33 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1173204-81-3
-
Appearance Solid
-
Masse moléculaire 570.65
-
Formule C29H34N10O3
-
Color White to off-white
-
SMILES
CCN1N=NC2=C1N=C(N=C2N3CCOCC3)C4=CC=C(C=C4)NC(NC5=CC=C(C=C5)C(N6CCN(CC6)C)=O)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Sci Transl Med
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]2018 Jul 18;10(450):eaaq1093. PMID: 30021885 -
J Exp Clin Cancer Res
Mechanisms of neural infiltration-mediated tumor metabolic reprogramming impacting immunotherapy efficacy in non-small cell lung cancer. [Abstract]2024 Oct 10;43(1):284. PMID: 39385213 -
Cell Prolif
Inhibition of PI3K/mTOR increased the sensitivity of hepatocellular carcinoma cells to cisplatin via interference with mitochondrial-lysosomal crosstalk. [Abstract]2019 May;52(3):e12609. PMID: 31033054
PKI-402 purchased from MedChemExpress. Usage Cited in: Cell Prolif. 2019 May;52(3):e12609. [Abstract]
Huh7 cells were treated with 8 μg/mL cisplatin and/or 5 μmol/L PKI‐402 in the presence or absence of 5 μmol/L E‐64 for 24 h and then stained with MitoSOX Red and detected using flow cytometry.
-
Int Immunopharmacol
Targeting periodontal inflammatory microenvironment to ameliorate periodontitis: A nitrogen ions implantation technique. [Abstract]2025 Dec 24:170:116055. PMID: 41448003 -
Int Immunopharmacol
Equine β-defensin 1 regulates cytokine expression and phagocytosis in S. aureus-infected mouse monocyte macrophages via the Paxillin-FAK-PI3K pathway. [Abstract]2023 Oct:123:110793. PMID: 37582311 -
Molecules
In Vitro and in Vivo Activity of mTOR Kinase and PI3K Inhibitors Against Leishmania donovani and Trypanosoma brucei. [Abstract]2020 Apr 23;25(8):1980. PMID: 32340370 -
Sci Rep
QSAR analysis on a large and diverse set of potent phosphoinositide 3-kinase gamma (PI3Kγ) inhibitors using MLR and ANN methods. [Abstract]2022 Apr 12;12(1):6090. PMID: 35414065 -
Lung
Overexpression of BPIFB4 Alleviates COPD Inflammatory Damage by Inhibiting M1 Macrophage Activation via the PI3K/AKT Pathway. [Abstract]2025 Jun 16;203(1):69. PMID: 40524026 -
J Biochem Mol Toxicol
RNA-Binding Protein DHX9 Enhances Radioresistance in Metastatic Hepatocellular Carcinoma by Activation of the PI3K/Akt Pathway Through Enhanced EEF1A2 mRNA Stability. [Abstract]2025 Jun;39(6):e70356. PMID: 40522266 -
Chem Biodivers
Jatrorrhizine Exhibits an Antitumor Effect Against Gefitinib-resistant Non-small Cell Lung Cancer via Inhibiting PI3K/mTOR Phosphorylation. [Abstract]2025 Jun;22(6):e202402598. PMID: 39924447 -
Heliyon
Dual blockage of PI3K-mTOR and FGFR induced autophagic cell death in cholangiocarcinoma cells. [Abstract]2024 May 10;10(10):e31112. PMID: 38799762
Solvant et solubilité
DMSO : 5 mg/mL (8.76 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 1.43 mg/mL (2.51 mM); Suspended solution; Need ultrasonic
Protocole
Enzyme assays are done in fluorescent polarization (FP) format. Human class I PI3Ks and PI3K-α mutants (E545K and H1047R) are produced in Sf9. GST-GRP1 (murine) is produced in Escherichia coli and isolated by GST-Sepharose. Assay buffers are reaction buffer [20 mM HEPES (pH 7.1), 2 mM MgCl2, 0.05% CHAPS, and 0.01% β-mercaptoethanol] and stop/detection buffer [100 mM HEPES (pH 7.5), 4 mM EDTA, 0.05% CHAPS]. FP reaction is run for 30 min at room temperature in 20 μL of reaction buffer containing 20 μM phosphatidylinositol 4,5-bisphosphate (PIP2), 25 μM ATP, and <4% DMSO (compound solvent). FP reaction is stopped with 20 μL of stop/detection buffer (10 nM probe and 40 nM GST-GRP), and after 2 h, data are collected. Selectivity of PKI-402 is evaluated in the 236 human kinase panel at [ATP]=Km for each enzyme[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MDA-MB-361, MDA-MB-468, T47D, MCF7, BT474, HT29, HCT116, DLD1, U87MG, H157, NCI-H460, A549, NCI-H1975, NCI-H1650, NCI-H2170, KB, 786-0, A498, MIA-PaCa-2, and PC3 cell lines are propagated at 37°C in 5% CO2 incubators in supplier-recommended growth medium. Cell growth inhibition is determined using the CellTiter 96 AQueous proliferation assay. Data are collected after 72 h using a Wallac Victor2 V 1420 multilabel HTS counter. FOXO-GFP translocation in U2OS cells is quantified after 60-min PKI-402 exposure using a Cellomics ArrayScan VTI Reader[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[1]
PKI-402 or vehicle is administered by i.v. route. Nude mice bearing MDA-MB-361 tumors are used. Tumor weight is calculated. Pharmacodynamic (biomarker) measurements are done on tumor-bearing female nude mice administered PKI-402. Tumor or normal tissue samples are collected from euthanized animals, homogenized, washed twice with cold (4°C) PBS, and then treated with cell lysis buffer[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (278 KB)
-
SDS (536 KB)
- English - EN (536 KB)
- Français - FR (536 KB)
- Deutsch - DE (536 KB)
- Norwegian - NO (536 KB)
- Español - ES (536 KB)
- Swedish - SV (536 KB)
- Italian - IT (536 KB)
- Korean - KR (536 KB)
- Portuguese - PT (536 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7524 mL | 8.7619 mL | 17.5239 mL | 43.8097 mL |
| 5 mM | 0.3505 mL | 1.7524 mL | 3.5048 mL | 8.7619 mL |